Gilead Sciences has entered into a definitive agreement to acquire Ouro Medicines, a NewCo formed in partnership with Keymed Biosciences, for up to USD 2.175 billion. The deal comprises an upfront payment of approximately USD 1.675 billion (subject to customary adjustments) and up to USD 500 million in potential milestone payments. Keymed, a shareholder in Ouro, will receive approximately USD 250 million from the upfront payment and is eligible for up to USD 70 million in milestones, for a total potential consideration of about USD 320 million.

Ouro's sole asset is gamgertamig, a bispecific T-cell engager (TCE) targeting BCMA and CD3 developed by Keymed for the treatment of autoimmune diseases. The candidate has received fast track and orphan drug (ODD) designations in the US for autoimmune haemolytic anaemia (AIHA) and immune thrombocytopenia (ITP). The acquisition by Gilead is intended to accelerate the global development of gamgertamig, with registrational studies anticipated to commence in 2027. Following the transaction, Keymed's original licensing agreement with Ouro, granting rights to the asset outside Greater China, will remain in effect.

PharmCube's NextBiopharm® database lists 13 indications for which gamgertamig is being developed. Click here to request a free trial for NextBiopharm®.